A-T Research and Therapy Pipeline
|
|
- Eunice Gray
- 6 years ago
- Views:
Transcription
1 L-Dopa (approved drug), ATCC, JHH Amantadine (approved drug), Nissenkorn 4-AP (approved drug), Shaikh/ATCC, JHH Baclofen (approved drug), ATCC, JHH Inositol (supplement), Berry ALA/Nicotinamide (supplements), ATCC GVT/MSL, Wong/BachPharma EUK-207, Malfroy/BioMarin DPUFAs, Retrotope Betamethasone (approved drug), Pignata/Kumada EryDex (approved in Italy), Chessa EryDex, EryDel (USA) ATM Lentiviral vector, Esteves ATM Lenti / transposon, Molina A-T hescs and ca-t hescs, Xu A-T ipscs, Lavin and others Ataxic (?) KO mouse, Proschel ATM missense and KO rat, Lavin A-T piglets, Pearce/Exemplar Primary PTC read through (RT) compounds, Gatti Splice altering compounds, Gatti PET/fMRI, Volkow DTI/PET, Rose MRI/MRS, Auer Inspiratory muscle training, Ross Exercise, Ross For FA A-T Research and Therapy Pipeline Approval Phase 3 Phase 2-Large Phase 2-Small Phase 1 Preclinical Development Research and Discovery Modulate neuronal transmission or circuitry Decrease oxidative stress Corticosteroid treatment Gene therapy Stem-cells Animal models with a neurological phenotype Mutationtargeted therapies Neuro-imaging Physical therapies
2 Modulate neuronal transmission or circuitry L-dopa A small study of this drug, which is used to treat Parkinson s disease, was carried out at the Johns Hopkins A-T Clinical Center in 1998 with mixed results. There is some interest in carrying out a larger study, perhaps focusing on people with symptoms arising from dysfunction of the basal ganglia or extra-pyramidal system, rather than pure ataxia. Amantadine Andrea Nissenkorn, of the Safra Children s Hospital, in Tel Aviv has conducted a small trial of amantadine sulphate, a drug similar to L-dopa, to treat ataxia and other neurological symptoms of A-T with reasonably positive results. She would like to conduct a larger scale trial. 4 A-P 4-Aminopyridine is a drug that has been used to treat the symptoms of multiple sclerosis and some other ataxias. A small-scale study is currently being set up at the Johns Hopkins A-T Clinical Center to evaluate whether there might be benefit in carrying out a larger study. Baclofen A study into the effects of this drug in improving eye movement and tremors in A-T was recently completed at the Johns Hopkins A-T Clinical Center. Results have not yet been published. Decrease oxidative stress Inositol A study was carried out in the late 1990s by Gerard Berry at the Children s Hospital of Pennsylvania. While there was no objective evidence of improvement in neurological or immunological symptoms, some parents reported improvements in mood or behaviour. ALA and Nicotinamide A study of the effects of nicotinamide and the anti-oxidant alpha-lipoic-acid was carried out in 2005 at the Johns Hopkins A-T Clinical Center. While there was an improvement in laboratory markers of oxidative stress and some improvement in lymphocyte counts there was no other significant clinical gain though the study did yield an accurate and reproducible means of measuring lung function in A-T. GVT/MSL EUK 207 DPUFAs, Bach Pharma, in association with Paul Wong of the MD Anderson Cancer Centre, University of Texas, is looking to organise a trial of Monosodium Luminol (MSL/GVT), a known drug with immune modulatory properties, in two to five year olds with AT. They would like to start a small Phase 1 study focusing on safety in July Bernard Malfroy-Carmine, of Mindset Rx, is looking to establish a clinical trial in children of the anti-oxidant drug EUK-207, the license for which is currently held by BioMarin. EUK-207 had an effect in treating the neuro-behavioural defect in A-T-null mice. Polyunsaturated fatty acids (PUFAs) are essential to cells in the nervous system, but are susceptible to oxidative damage, possibly leading to neurological deterioration. The company Retrotope is attempting to stabilize the PUFAs and protect cells from this
3 oxidative damage by using mimetics (very similar chemical substitutes) of PUFAs known as DPUFAs (deuterated PUFAs). They are hoping to start a trial DPUFAs in patients with Friedreich s Ataxia in If successful, it may be possible to establish a trial in patients with A-T. Cortico-steroid treatment Luciana Chessa, Sapienza University, Rome, conducted a small-scale trial (non-placebo controlled) of dexamethasone delivered via infusion into the patients own red blood cells. Around half of those tested responded to the treatment and had a positive benefit. The company that has a patent on this mode of treatment has just got approval from the United States FDA for its machine and is planning to organize a Phase I trial in the USA. An international group including Luciana Chessa (above), William Whitehouse, Nottingham University Hospitals, and Kate Sinclair, Royal Brisbane Children s Hospital are seeking funding for a 3-centre efficacy trial of low-dose oral betamethasone, to follow up the encouraging results of a very small scale study in Italy. Satoko Kumada, Tokyo Metropolitan Neurological Hospital, is also undertaking a small-scale study of betamethasone in A-T. Gene therapy Miguel Esteves, University of Massachusetts Medical School, has developed a lentiviral vector for the A-T protein (ATM) is now assessing the most effective way to test this vector. Ignacio Molina, University of Granada, has received a grant from the joint fund established by the A-T Society, Action for A-T and Sparks for a gene therapy project. He has developed lentiviral vector for an ATM minigene and is working to see if the minigene can express a fully functioning protein. Dr. Molina is also attempting to resolve difficulties in producing large quantities of the vector. Stem-cells Yang Xu, University of California, San Diego, has developed both a line of ATM-null human embryonic stem-cells (hescs) and a line of conditional hescs, in which the functioning of ATM protein can be switched on and off. Martin Lavin, Queensland Institute of Medical Research has generated both induced pluripotent stem cells (ipsc) from patient fibroblasts and olfactory neurosphere derived stem (ONS) cells from patient olfactory mucosa. They have characterised both cell types and demonstrated that they can be differentiated into functional neurons, thus representing a useful resource for further study of the pathogenesis of A-T for screening potential therapeutics.
4 Animal models with a neurological phenotype Margot Mayer-Proschel, University of Rochester, USA, has developed a strain of ATM knockout mice (ATM fl/fl x CMVcre), which appear to display a clear neurological phenotype whereas other strains of ATM knockout mice do not do so. The low number of mice bred so far means these mice require further characterization and work continues. Martin Lavin, Queensland Institute of Medical Research, is developing colonies of rats with both ATM-knockout and missense mutations. Both strains appear to show neurological deficits, but irregularly, and work continues. David Pearce and Exemplar Genetics in the USA are working to develop an ATM-knockout pig, with the aim of generating a neurological phenotype more similar to that in humans. Heterozygote piglets (carriers of one knock-out gene) have been made but as yet, no homozygotes.(with two knock-out genes) have been produced. Mutation-targeted therapies Richard Gatti at UCLA has been working for some years on identifying small molecules that will enable cells to read through a particular kind of mutation known as a nonsense mutation (sometimes also stop codon or primary premature termination codon ). Some promising compounds have been identified, and Dr. Gatti is trying to find a pharma company willing to invest in the extremely expensive process of developing the drugs for clinical trials in humans. Around half of all A-T mutations are so-called splicing mutations. Richard Gatti has demonstrated that chemical compounds called splice-switching oligoneucleotides have the ability to restore gene expression (hence the production of functioning ATM protein) in ATM deficient cells in the laboratory. Neuro-imaging Norah Volkow, Brookhaven National Laboratory, New York, is carrying out a study using PET scanning and functional MRIs to study brain metabolism and functional interaction between brain cells in adult patients with A-T. Much data has been gathered and is being elaborated (or analysed ), but early results show very interesting variations from the scans of non-a-t control subjects. Dr Stephen Rose, at the University of Queensland, is leading a programme involving scans of the brains of young patients with A-T. He is examining cerebellar white matter motor pathways using diffusion MRI and neuro-inflammation using PET scans. The study aims to improve our understanding of the how neurodegenerative processes affect individuals and to identify neuro-imaging biomarkers for future therapeutic interventions. Dorothee Auer, at Nottingham University, is seeking funding for a project to use Functional MRI and MR spectroscopy to develop biomarkers for measuring neurodegeneration and for identifying and monitoring the mechanism of action of anti-oxidant therapies. This study would complement the two outlined above.
5 Physical therapies Emma Ross, at the University of Brighton, is studying whether breathing training delivered via a hand-held inspiratory muscletraining device improves lung function, cough effectiveness and quality of life in individuals with A-T. Although the benefits of exercise are well documented, no studies have investigated the effect of an exercise intervention in people with A-T. In this project, Dr Ross aims to examine if exercise can improve muscle function and movement coordination, which will in turn improve the ability to perform daily tasks, increase confidence and psychological wellbeing. Produced March 2013 by the A-T Society and the A-T Children s Project
Understanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationQPS Neuropharmacology Overview
HISTOCHEMISTRY HISTOLOGY KO MODELS IN VIVO MODELS BLOOD BRAIN BARRIER IN VITRO MODELS NEUROPHARMACOLOGY OVERVIEW NEUROSCIENCES QPS Neuropharmacology Overview QPS is recognized all over the world as a leading
More informationGene therapies for SMA and DMD
Gene therapies for SMA and DMD Annemieke Aartsma-Rus September 2018 Disclosures Employed by LUMC, which has patents on exon skipping technology, some of which has been licensed to BioMarin and subsequently
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationNEUROLOGY AND OPHTHALMOLOGY
NEUROLOGY AND OPHTHALMOLOGY OPPORTUNITIES AT INSERM BD & L: Anne Cochi anne.cochi@inserm-transfert.fr September 2017 1 WE PROPOSE A SELECTION OF PROJECTS AT DIFFERENT STAGES 4 Neurodegeneration patents
More informationPlenary Session: An update of brain circuits in Parkinson s and Deep Brain Stimulation
Plenary Session: An update of brain circuits in Parkinson s and Deep Brain Stimulation Deep Brain Stimulation Andres M Lozano, University of Toronto Deep brain stimulation is the delivery of an electrical
More informationFRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting
FRDA CLINICAL TRIALS Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center US STUDIES FUNDED BY FARA, MDA, NAF, AND NIH FOR FA 18 16 14 12 10 8 6 4 2 0 1997 1998 1999 2000 2001 2002
More informationThe NYSCF Research Institute
Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationPress Release. Interim Data Summary
Print Page Close Window Press Release bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D at AAN 2016 Annual Meeting First clinical data to be presented from Phase 2/3 Starbeam Study;
More informationCOMPASS. Cure SMA Awards 10 New Grants in Basic and Clinical Care Research. A Publication Dedicated to Research Updates SPRING 2016
BASIC RESEARCH DRUG DISCOVERY CLINICAL TRIALS CLINICAL CARE RESEARCHER MEETING LATEST ADVANCES COMPASS A Publication Dedicated to Research Updates SPRING 2016 Cure SMA Awards 10 New Grants in Basic and
More informationCOMPASS. Meet Our Recipients: Understanding the Pathology of SMA. A Publication Dedicated to Research Updates SUMMER 2018
COMPASS A Publication Dedicated to Research Updates Cure SMA has a rich history of supporting research aimed at improving quality of life, expanding treatment options, and advancing the understanding of
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationOverview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014
Genetics where is it leading us? Jill Goldman, MS, MPhil, CGC Taub Institute Columbia University Medical Center Overview Why are there so many research studies on the genetics of? How much of is genetic?
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationPATIENT GROUPS & CLINICAL TRIALS CASE STUDY
February 1, 2017 PATIENT GROUPS & CLINICAL TRIALS CASE STUDY Jeffrey W. Sherman, M.D., FACP Past President Inaugural Fellow Chief Medical Officer Executive Vice President Disclaimer The views and opinions
More informationStealth BioTherapeutics Mission:
The following is a summary of a live presentation offered through joint collaboration with UMDF, MitoAction and the Foundation for Mitochondrial Medicine to the mitochondrial disease patient and family
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationCatabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress -- MoveDMD Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying
More informationResearch collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017
Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao 1 29 th November, 2017 Collaboration with Q therapeutics to develop new ipsc therapies for CNS diseases REPROCELL announced a
More informationChapter 8 Healthcare Biotechnology
Chapter 8 Healthcare Biotechnology Outline: 8.1 Introduction 8.2 Biopharming 8.3 Models of Human Disease 8.4 Detecting and Diagnosing Human Disease 8.5 Monoclonal Antibodies 8.6 Gene Therapy 8.7 Tissue
More informationStem Cells: Introduction and Prospects in Regenerative Medicine.
Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,
More informationAlexandra Richardson, PhD, CLP April 2015
Alexandra Richardson, PhD, CLP April 2015 Clayton Biotechnologies, Inc. is a for-profit company which facilitates the commercialization of medical discoveries made by the Clayton Foundation for Research
More informationAre remyelination strategies realistic?
Presenter: Benjamin Greenberg, MD, MHS University of Texas Southwestern and Children s Medical Center Transcription from presentation available at https://youtu.be/npsgkpaqeyg 00:00 This afternoon even
More informationThe New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017
The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,
More informationUpdating International Ethics Guidelines for Stem Cell Research
Updating International Ethics Guidelines for Stem Cell Research Jeremy Sugarman, MD, MPH, MA Harvey M. Meyerhoff Professor of Bioethics & Medicine Department of Medicine Berman Institute of Bioethics Johns
More informationMolecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics
Molecular Medicine Molecular Medicine Stem cell therapy Gene therapy Tumor therapy Immunotherapy Other therapies Vaccines Genetic diagnostics Medical genomics Medication Diagnostics medicine: old desire
More information1: Executive Summary The Brain Industry Revealed Neuropharmaceuticals Cell Therapies Neurodevices Neurodiagnostics Investment Risks and Opportunities
1: Executive Summary The Brain Industry Revealed Neuropharmaceuticals Cell Therapies Neurodevices Neurodiagnostics Investment Risks and Opportunities Translating Neuroscience into Neurotech The Neurotech
More informationMY PERSONAL MEMORIES OF RITA LEVI-MONTALCINI G. NISTICÒ
Vol. 2, no. 1, 1-3 (2013) MY PERSONAL MEMORIES OF RITA LEVI-MONTALCINI G. NISTICÒ General Director of the European Brain Research Institute (EBRI, Rita Levi-Montalcini Foundation) Vol. 2, no. 1, 5-17 (2013)
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationTowards a stem cell based therapy for Parkinson s Disease
Stem cell based therapies for Parkinson s Disease Towards a stem cell based therapy for Parkinson s Disease MALIN PARMAR NYSCF Robertson Investigator Lund University, Sweden INTR, Port Douglas, Sept 13-16,
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationWill Stem Cells Finally Deliver Without Controversy?
Will Stem Cells Finally Deliver Without Controversy? Keith Gary, Ph.D. Director of Program Development Kansas City Area Life Sciences Institute Olathe North Life Sciences 1 February 2012 What s the Buzz?
More informationCAP-1002: HOPE Clinical Trials PPMD Annual Conference 2018
CAP-1002: HOPE Clinical Trials PPMD Annual Conference 2018 1 Capricor, Inc. PPMD Annual Conference June 2018 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationPrograma Cooperación Farma-Biotech Neurociencias G79
G79 A Neuroprotective Therapy Barcelona, 15 de febrero 2011 Content 1. The Company 2. The Product a) Therapeutic focus b) Innovative mechanisms of action c) Differential features facing the market d) Current
More informationPfizer Program in DMD. Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017
Pfizer Program in DMD Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017 Myostatin Inhibitor for the Potential Treatment of Duchenne Muscular Dystrophy Disclaimer This presentation includes
More informationInnovative treatments in neuromuscular disorders
Innovative treatments in neuromuscular disorders Great Ormond Street Hospital for Children NHS Foundation Trust Practical Neurology Study Days 2018 Francesco Muntoni Dubowitz Neuromuscular Centre UCL Institute
More informationNEWSLETTER MAY To Our Shareholders:
NEWSLETTER MAY 2017 To Our Shareholders: I appreciate your interest in the work done by NeOnc Technologies, Inc. (NTI) and your continued trust. I want to update you on the progress of our activities in
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationEHE Group Research Update
THE EHE FOUNDATION THE EHE RARE CANCER CHARITY (UK)* THE EHE RARE CANCER FOUNDATION (AUSTRALIA)* * Currently awaiting registration EHE Group Research Update Dr Rubin s EHE research progress Genetic basis
More informationThe Leader in AAV Gene Therapy. A Guide to AAV Gene Therapy for MPS I and II
The Leader in AAV Gene Therapy A Guide to AAV Gene Therapy for MPS I and II REGENXBIO seeks to understand the diverse perspectives of patients, caregivers and families, and to learn from their experiences
More informationA roadmap for bringing FKRP gene therapies into clinical use
A roadmap for bringing FKRP gene therapies into clinical use Jeffrey S. Chamberlain, Ph.D. McCaw Chair in Muscular Dystrophy Wellstone Muscular Dystrophy Research Center - Seattle Depts. of Neurology,
More informationThe Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
More informationClinical Trial Paradigms in CNS Gene Therapy. Bernard Ravina, MD, MS Chief Medical Officer, Praxis Precision Medicines October 16, 2018
Clinical Trial Paradigms in CNS Gene Therapy Bernard Ravina, MD, MS Chief Medical Officer, Praxis Precision Medicines October 16, 2018 Disclosures Employee, Praxis Medicines Advisor, Voyager Therapeutics
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationThe Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation
The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation 1 st Annual FTD Caregiver Conference Raleigh, NC July 12, 2011 Our objectives today Snapshot of medical research process
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationRegulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy?
Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy? EPLS September 24, 2014 Ulrich Granzer Granzer Regulatory Consulting & Services The Challenge: What needs to be done
More informationFSHD: Clinical Trial Preparedness
FSHD: Clinical Trial Preparedness Rabi Tawil, MD University of Rochester Medical Center FSHD Clinical Trials Readiness Workshop Newcastle, October 31, 2013 Developing an FSHD Clinical Trial Toolkit Why
More informationStem Cells in Life and Disease: Immortality Inside You
Stem Cells in Life and Disease: Immortality Inside You Blair Benham-Pyle Tyler Burns Joe Ouadah Splash! Fall 2011 What do you think a stem cell is? (discuss with people around you) A stem cell is a cell
More informationOUR WISH LIST RESEARCH EQUIPMENT
OUR WISH LIST RESEARCH EQUIPMENT YOU CAN MAKE A TANGIBLE DIFFERENCE! The South Australian Health and Medical Research Institute (SAHMRI) is one of the most exciting developments in the field of health
More informationOUR WISH LIST RESEARCH EQUIPMENT
OUR WISH LIST RESEARCH EQUIPMENT WITH YOUR PHILANTHROPIC SUPPORT, WE CAN WORK TOGETHER TO COMPLETE OUR FULLY-FUNCTIONAL FACILITY BY PURCHASING THE CUTTING-EDGE EQUIPMENT AND RESOURCES TO SUPPORT SAHMRI
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationThe Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
More informationHow to measure the effectiveness of therapy by measuring oxygenation of the target tissues
How to measure the effectiveness of therapy by measuring oxygenation of the target tissues Harold Swartz, M.D., Ph.D. Geisel Medical School at Dartmouth Disclosures Scientific Director of Clin-EPR, LLC
More informationDiscovery and validation of novel
Webinar IMI2 - Call 12 Discovery and characterization of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases Discovery
More informationTherapeutic Cell Replacement. Steven McLoon Department of Neuroscience University of Minnesota
Therapeutic Cell Replacement Steven McLoon Department of Neuroscience University of Minnesota 1 Neuronal Death Neurons are lost due to four main causes: Trauma Toxin Hypoxia (typically loss of air or blood
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More information10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised
DNA/RNA therapies for Wilson s disease Julien Baruteau - Great Ormond Street Institute of Child Health, University College London, UK Metabolic Medicine, Great Ormond Street Hospital, London, UK PLAN Landscape
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationCBME/INSERM-Lille, France Mini-symposium
CBME/INSERM-Lille, France Mini-symposium Contribution of Tau studies to Neuroregenerative Medicine & Development of Biomedical Engineering Tools March 6 th, 2018 8.45 am 14.00 pm Da An Campus, Room B204
More informationUniversity of Eastern Finland (UEF) Main Research Lines
University of Eastern Finland (UEF) Main Research Lines Asla Pitkänen, MD, PhD Epilepsy Research Laboratory A.I.Virtanen Institute for Molecular Sciences University of Eastern Finland Kuopio, Finland E-mail:
More informationStem Cell Research 101
Stem Cell Research : A promising type of bioscience research The Stem Cell debate and the impact of the induced pluripotent stem cell procedure Why Is Vocabulary Important? Key terms frame the debate Mature
More informationCharacterization of Niemann-Pick Type C mutant mice using automated cage monitoring systems
Characterization of Niemann-Pick Type C mutant mice using automated cage monitoring systems Dr. Sangeetha V. Iyer Perlara PBC San Francisco, CA sangeetha@perlara.com Contents Introduction to Perlara PBC
More informationSevion Therapeutics, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Sevion Therapeutics, Inc. Form: 8-K Date Filed: 2017-06-28 Corporate Issuer CIK: 1035354 Copyright 2017, Issuer Direct Corporation. All Right Reserved. Distribution
More informationScience Dialogue. By: Dr. Ahmed Hegab, PhD Dr. Hiroshi Kubo, MD, PhD. Hachinohe-Kita High School
Science Dialogue at Hachinohe-Kita High School By: Dr. Ahmed Hegab, PhD Dr. Hiroshi Kubo, MD, PhD Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine Topics of today
More informationDuchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Clinical and Commercial Strategy Dr. Leslie Hudson, President and CEO September 10, 2008 Duchenne Muscular Dystrophy (DMD) Defects in the dystrophin gene; no protein expression
More informationNEWSLETTER. April
NEWSLETTER April 2018 www.nyrada.com Since the initial newsletter was posted in January, Nyrada has been busy transitioning into a fully functioning company with new staff joining and the development program
More informationAD/PD Conference, Nice, Fr, 2015
AD/PD Conference, Nice, Fr, 2015 Overview, novelties and conclusions for domestic research NAP B MTA TTK MS Neuroproteomics Group Overlaping molecular mechanisms of miss-folded protein based neurodegenerative
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationHandy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
The Center for Neural Development and Disease (will be The Center for NeuroTherapeutics Discovery) Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
More informationThe Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC
The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research
More informationDrug Repurposing at NCATS
Drug Repurposing at NCATS JOHN C. MCKEW, PH.D. ACTING SCIENTIFIC DIRECTOR, DIVISION OF PRE-CLINICAL INNOVATION, NCATS JUNE 24, 2013 IOM GENOMICS-ENABLED DRUG RPEPURPOSING AND REPOSITIONING TRND: Therapeutics
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationHemophilia and Gene Therapy
Hemophilia and Gene Therapy Jackie Chu June 4, 2008 Overview Hemophilia, the disease Gene therapy Hemophilia as a target for gene therapy Gene delivery systems Clinical trials New methods Future of gene
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More informationLecture 24 Differentiation and stem cells
Lecture 24 Differentiation and stem cells *Stem cells and differentiation in plants Totipotency Stem cells in animals Therapeutic use Cloning Therapeutic Reproductive Therapeutic cloning in humans Stem
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationSTEM CELLS IN NEUROLOGY ISABELLE COCHRANE MERIT
STEM CELLS IN NEUROLOGY BY ISABELLE COCHRANE MERIT RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract Ever since their discovery, stem cells have been heralded as the ultimate cure to
More informationMultiple Sclerosis Research Program
Multiple Sclerosis Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationTherapeutic Cell Replacement. Steven McLoon Department of Neuroscience University of Minnesota
Therapeutic Cell Replacement Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Coffee Hour Wednesday (Dec 13) Thursday (Dec 14) Friday (Dec 15) 9:00-10:00am Surdyk s Café in
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationNew Expanded and Extended Strategic Collaboration with Biogen
New Expanded and Extended Strategic Collaboration with Biogen April 20, 2018 On Today s Call Stanley Crooke, M.D., Ph.D. Chief Executive Officer and Chairman Ionis Pharmaceuticals Beth Hougen Chief Financial
More informationCNS Gene Regulation Platform
CNS Gene Regulation Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationRenew, Repair, Rejuvenate. Presented by: Clinton Howard at the 2012 Leadership Retreat Maui, Hawaii, September 29, 2012
Stem-Kine Renew, Repair, Rejuvenate Presented by: Clinton Howard at the 2012 Leadership Retreat Maui, Hawaii, September 29, 2012 I am pleased to have the opportunity to talk with you about one of the most
More informationStem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan
Stem Cells & Neurological Disorders Said Ismail Faculty of Medicine University of Jordan Outline: - Introduction - Types & Potency of Stem Cells - Embryonic Stem Cells - Adult Stem Cells - ipscs -Tissue
More informationcompact Mental Health
New Source of Excitatory Neurons Discovered in the Brain (Nature Neuroscience 12, 1524) Mouse Models for the Presymptomatic Phase of Parkinson s Disease (Genes Brain Behav. 2010 Apr;9 (3):305-1) Researchers
More informationPrecision Medicine in Sepsis
Precision Medicine in Sepsis Jean-Daniel Chiche, MD PhD jean-daniel.chiche@aphp.fr MICU & Dept Infection, Immunity & Inflammation Hôpital Cochin & Institut Cochin, Paris-F Sepsis 2017: a litany of failed
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More information